Pharmaceutical company Moberg Pharma AB (STO;MOB) on Monday reported net profit after tax of SEK12.3m, or diluted EPS of SEK0.71, for the third quarter of 2017, from July 2017 to September 2017.
This was in comparison with profit after tax of SEK12.8m, or diluted eps of SEK0.89, in Q3 2016.
Net revenues for the quarter were SEK108.3m, as compared with SEK104.1m in Q3 2016.
Moberg Pharma researches and produces topical treatments for skin conditions. The company is researching creams for nail fungus, dry and scaly skin, anal fissures and actinic keratosis.
(EUR1.00=SEK9.85)
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development